[go: up one dir, main page]

MX2018011799A - Formas de dosificacion de liberacion prolongada disuasivas de abuso. - Google Patents

Formas de dosificacion de liberacion prolongada disuasivas de abuso.

Info

Publication number
MX2018011799A
MX2018011799A MX2018011799A MX2018011799A MX2018011799A MX 2018011799 A MX2018011799 A MX 2018011799A MX 2018011799 A MX2018011799 A MX 2018011799A MX 2018011799 A MX2018011799 A MX 2018011799A MX 2018011799 A MX2018011799 A MX 2018011799A
Authority
MX
Mexico
Prior art keywords
dosage forms
abuse deterrent
extended release
deterrent dosage
crush
Prior art date
Application number
MX2018011799A
Other languages
English (en)
Inventor
Gaik Jonathan
Park Jaehan
Lathrop Ryan
Nichols Gary
Schallom John
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of MX2018011799A publication Critical patent/MX2018011799A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas de dosificación de liberación prolongada disuasivas de abuso que comprenden partículas de liberación controlada resistentes a la trituración que proporcionan propiedades disuasivas de abuso a las formas de dosificación. Las partículas de liberación controlada resistentes a la trituración, que comprenden polímeros plásticos/elásticos y al menos un ingrediente farmacéutico activo (API) o una sal farmacéuticamente aceptable de este, se preparan mediante un proceso de extrusión por fusión en caliente.
MX2018011799A 2016-03-31 2017-03-21 Formas de dosificacion de liberacion prolongada disuasivas de abuso. MX2018011799A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662315952P 2016-03-31 2016-03-31
PCT/US2017/023316 WO2017172406A1 (en) 2016-03-31 2017-03-21 Extended release, abuse deterrent dosage forms

Publications (1)

Publication Number Publication Date
MX2018011799A true MX2018011799A (es) 2019-01-24

Family

ID=59958479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011799A MX2018011799A (es) 2016-03-31 2017-03-21 Formas de dosificacion de liberacion prolongada disuasivas de abuso.

Country Status (8)

Country Link
US (3) US10624888B2 (es)
EP (1) EP3435984A4 (es)
JP (2) JP7023859B2 (es)
AU (1) AU2017241266B2 (es)
BR (1) BR112018069785A2 (es)
CA (1) CA3019335A1 (es)
MX (1) MX2018011799A (es)
WO (1) WO2017172406A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624888B2 (en) * 2016-03-31 2020-04-21 SpecGx LLC Extended release, abuse deterrent dosage forms
FR3070390A1 (fr) * 2017-08-25 2019-03-01 Eleonor Composition comprenant au moins un alcaloide de protoberberine et son procede de fabrication
KR102810926B1 (ko) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 남용 억제 황산모르핀 제형
WO2020068510A1 (en) * 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
WO2021188517A1 (en) * 2020-03-17 2021-09-23 Rutgers, The State University Of New Jersey Continuous melt-coating of active pharmaceutical ingredients using surfactants for dissolution enhancement
EP4135666A1 (fr) * 2020-04-17 2023-02-22 Eleonor Composition comprenant au moins un alcaloïde de protoberbérine et son procédé de fabrication
CN114073252B (zh) * 2020-08-12 2022-11-08 中国热带农业科学院环境与植物保护研究所 荔枝用展着剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
AU2002319774B2 (en) * 2001-08-06 2005-04-21 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US20030125347A1 (en) * 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
DE17154462T1 (de) * 2002-04-05 2019-12-19 Euro-Celtique S.A. Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
US20070190142A1 (en) * 2006-01-21 2007-08-16 Abbott Gmbh & Co. Kg Dosage forms for the delivery of drugs of abuse and related methods
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) * 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
AU2009207796B2 (en) * 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
US10751287B2 (en) * 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10154966B2 (en) * 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) * 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10624888B2 (en) * 2016-03-31 2020-04-21 SpecGx LLC Extended release, abuse deterrent dosage forms

Also Published As

Publication number Publication date
JP7366170B2 (ja) 2023-10-20
JP2022051901A (ja) 2022-04-01
JP2019510040A (ja) 2019-04-11
CA3019335A1 (en) 2017-10-05
EP3435984A1 (en) 2019-02-06
US20200268747A1 (en) 2020-08-27
US20230079134A1 (en) 2023-03-16
US20170281615A1 (en) 2017-10-05
BR112018069785A2 (pt) 2019-01-29
US12208094B2 (en) 2025-01-28
EP3435984A4 (en) 2019-11-06
JP7023859B2 (ja) 2022-02-22
WO2017172406A1 (en) 2017-10-05
AU2017241266A1 (en) 2018-10-18
US11446293B2 (en) 2022-09-20
US10624888B2 (en) 2020-04-21
AU2017241266B2 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2018011799A (es) Formas de dosificacion de liberacion prolongada disuasivas de abuso.
IL288554A (en) Controlled release of amphetamine, drug meters and dosage forms with abuse deterrence
LT3724891T (lt) Vaistų injekcijos ir ligų valdymo sistemos, įrenginiai ir būdai
EP3294398A4 (en) SYSTEM AND METHOD FOR THE ADMINISTRATION OF MEDICAMENTS
EP3710079A4 (en) SYSTEMS, DEVICES, FORMULATIONS AND PROCEDURES FOR CONTROLLED INGREDIENT DELIVERY
EP3313499A4 (en) DEVICES, SYSTEMS AND METHODS FOR INCREASING THE INTRALUMINAL DRUG DELIVERY AND RECEIVING
EP3402548C0 (en) OCCLUSION RESOLUTION IN DRUG DELIVERY DEVICES, SYSTEMS, AND METHODS
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2015000114A (es) Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada.
EP3801678A4 (en) MEDICATION INFUSION DEVICES, SYSTEMS AND METHODS
EP3445416A4 (en) ENTERALES ACTIVE COMPOSITION SYSTEM
MX2017016802A (es) Formulaciones farmaceuticas.
EP3318282A4 (en) AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF
PH12016501841A1 (en) Immunosuppressant formulation
EP3643353A4 (en) ROBOTS FOR DRUG DISPENSING
IL276290A (en) Heteroaryl compounds, their pharmaceutical preparations and their medical use
WO2017079403A3 (en) Polymeric nanoparticles
EP3323066A4 (en) MEDICAMENT IDENTIFICATION, PURSUIT AND CONTINUATION MANAGEMENT
DK3630061T3 (da) Udfældningsresistente, småmolekylære lægemiddelformuleringer
JP2017197541A5 (es)
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
PH12018501758A1 (en) Oritavancin formulations
EP3733243A4 (en) METHOD OF DRUG ADMINISTRATION